

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 3, 2017
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 3, 2017.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Kashyap Patel, MD
Philip Mubarak, MD
Thomas Phillips, RPh

Tan Platt, MD
Edward Behling, MD
Gregory Browning, MD

Cheryl Hartvigsen, RPh
Joni Bollinger, MD

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Janet Giles
Constance Holloway, JD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 2, 2016

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Boehringer Ingelheim	Julie O'Malley	COPD
Otsuka	Jason Swartz, RPh, MBA	Antipsychotics, Oral

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

- Respiratory, Anticholinergics (COPD)
- GI Motility, Chronic
- Antidepressants, SSRIs
- Statins
- Antipsychotics, Oral
- Growth Hormone
- Epinephrine, Self-Injected

The chart below represents the recommendations from the P & T Committee:

RESPIRATORY, ANTICHOLINERGICS (COPD)	
Preferred	Non-Preferred
Atrovent HFA Spiriva Handihaler Stiolto Respimat‡	Anoro Ellipta Bevespi Aerosphere Combivent Respimat Daliresp Incruse Ellipta Seebri Neohaler Spiriva Respimat Tudorza Pressair Utibron Neohaler

GI MOTILITY, CHRONIC	
Preferred	Non-Preferred
Amitiza Linzess Movantik‡	Lotronex Relistor Viberzi Xifaxan

ANTIDEPRESSANTS, SSRIs	
Preferred	Non-Preferred
Citalopram	Celexa
Escitalopram‡	Lexapro
Fluvoxamine	Paxil CR
Fluoxetine	Paxil
Paroxetine IR	Pexeva
Sertraline	Prozac/Prozac weekly (60mg/90mg)
	Sarafem
	Sertraline
	Trintellix
	Zoloft

STATINS	
Preferred	Non-Preferred
Atorvastatin	Altoprev
Lovastatin	Crestor
Pravastatin	Lescol XL
Rosuvastatin‡	Lipitor
Simvastatin	Pravachol
	Vytorin
	Zocor

ANTIPSYCHOTICS, ORAL	
Preferred	Non-Preferred
Aripiprazole tabs‡	Abilify
Clozapine	Clozaril
Latuda	Fanapt+‡
Olanzapine	Fazaclor
Quetiapine	Geodon
Risperidone	Invega
Saphris	Nuplazid
Ziprasidone caps	Rexulti
	Risperdal
	Seroquel
	Seroquel XR
	Symbyax
	Versacloz
	Vryalar
	Zyprexa

GROWTH HORMONE

Preferred	Non-Preferred
Genotropin ‡(Cartridge/syringe) Norditropin Pen	Humatrope Nutropin AQ+‡ Omnitrope Saizen Zomacton Zorbtive

EPINEPHRINE (INJECTABLES)	
Preferred	Non-Preferred
Epinephrine 0.3mg (AG)‡ Epinephrine 0.15mg (AG)‡	Adrenaclick Auvi-Q Epi Pen / Epi Pen Jr+.

‡ Indicates "Added as Preferred"

+ Indicates "Moved to Non-Preferred"

5. Old Business

None

6. New Business

Lisa presented new drugs to market. Bryan advised the Committee of organizational changes. Former Director, Christian Soura, resigned as of April 7, 2017. Deidre Singleton is the acting Director and Bryan will fill the acting Deputy Director position.

Bryan also advised the Committee that effective July 1, 2017 all smoking cessation agents will be available with no prior authorization (PA) and no copay requirements. The monthly script limitations will be eliminated effective July 1, 2017 as well. Treatment of opioid abuse (MAT) will be moving to a protected class as well. P&T will develop a sub-committee to open discussions.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Classes for Re-Review

- Respiratory, Anticholinergics (COPD)
- GI Motility, Chronic
- Antidepressants, SSRIs
- Statins
- Antipsychotics, Oral
- Growth Hormone
- Epinephrine, Self-Injected

8. **Closing Comments**

The next meeting will be held on Wednesday, June 7, 2017, at 4:00 p.m. Note: Meeting moved to September 6, 2017.

9. **Adjournment**

The meeting adjourned at 5:45 p.m.